Can a Split-Type robot improve surgery for a challenging cancer?

NCT ID NCT07790809

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This trial tests a split-type robotic system for removing Siewert type II/III gastroesophageal junction cancer, a tumor at the junction of the esophagus and stomach. The study will enroll 25 patients who need curative surgery. Researchers will measure how often the robotic procedure is completed without switching to another method, and how many complications occur within 30 days. The goal is to see if this robotic approach is safe and feasible for this complex surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Robotic-assisted radical resection using a split-type modular robotic system
What this could lead to
If successful, this could support the use of split-type robotic systems for complex gastroesophageal junction cancer surgery, potentially improving recovery and surgical precision.
What could go wrong
This is a small, early-stage study with only 25 participants, so results may not apply broadly. Robotic surgery carries risks like complications or the need to switch to open surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years, inclusive, regardless of sex. 2. Histologically and/or cytologically confirmed Siewert type II or type III gastroesophageal junction tumor, with clinical staging according to AJCC 8th edition TNM classification indicating suitability for curative surgical resection. 3. Adequate organ function as assessed by the investigator before surgery. 4. Provision of written informed consent and willingness to participate in the study. 5. Ability and willingness to comply with study procedures and follow-up requirements. 6. ECOG performance status of 0-1. 7. Absence of distant metastasis confirmed by preoperative thoracoabdominal and pelvic CT or PET-CT. Exclusion Criteria: 1. Patients with body mass index (BMI) \<18.5 kg/m² or BMI ≥35 kg/m². 2. Patients with severe cardiac, pulmonary, neurological, hepatic, or renal diseases that may prevent tolerance of surgery or anesthesia. 3. Patients unable to tolerate pneumoperitoneum or considered by the investigator to have extensive intra-abdominal adhesions or other conditions preventing safe establishment of pneumoperitoneum. 4. Patients with severe coagulation disorders that contraindicate minimally invasive surgery. 5. Patients with active pulmonary tuberculosis. 6. Patients with severe uncontrolled diseases, acute infections, severe physical deterioration, massive ascites, active intra-abdominal bleeding, or shock. 7. Patients with metastatic lymph nodes fused together or encasing major blood vessels, making curative resection infeasible. 8. Patients with previous abdominal/pelvic surgery, radiotherapy, or chemotherapy that may affect the feasibility of laparoscopic or robotic surgery. 9. Pregnant or breastfeeding women. 10. Patients currently participating in other clinical trials involving investigational drugs or medical devices. 11. Patients considered unsuitable for this study by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Siewert type II/III gastroesophageal junction adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Hospital of Jilin Universiry

    RECRUITING

    Changchun, Jilin, 130021, China